Swift Biosciences

The sample prep technologies firm intends to use the funding to expand its commercial channels, among other things.

A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.

The partners plan to improve yields from small input samples and provide better sequencing libraries.

Both partners believe the agreement will help expand the scope of their services and give them additional markets for their products.  

The companies will combine their technologies to create workflows for the next-generation sequencing of tumor cells obtained from FFPE samples. 

The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.

Swift will incorporate Horizon Discovery's NGS reference standards as a positive control in its oncology panel.

Researchers hope that newfound genetic information will help conservation efforts for the vaquita porpoise. 

The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.

Agilent Technologies has optimized its SureSelect Target Enrichment solution for Life Technologies' Ion Proton.

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.